度普利尤单抗治疗慢性鼻窦炎伴鼻息肉的真实世界有效性:匈牙利八中心12个月随访结果
该研究纳入匈牙利八个转诊中心的135例成人未控制慢性鼻窦炎伴鼻息肉患者,接受度普利尤单抗300 mg每两周皮下注射,随访6和12个月。结果显示所有临床参数均显著改善,安全性良好,无严重副作用,无需补救治疗。真实世界结果表明持续度普利尤单抗治疗在CRSwNP及2型共病(如支气管哮喘和NERD)中有效且安全。
要点
- 135例未控制CRSwNP患者接受度普利尤单抗300 mg每两周皮下注射,随访6和12个月。
- 治疗6和12个月后所有临床参数均显著改善,安全性良好,无严重副作用,无需补救治疗。
- 真实世界结果表明持续度普利尤单抗治疗在CRSwNP及2型共病中有效且安全。
核心结论
- 真实世界研究显示持续度普利尤单抗治疗在CRSwNP及支气管哮喘、NERD等2型共病中有效且安全。
研究设计与样本
- 研究纳入匈牙利八个转诊中心自2020年起接受度普利尤单抗治疗的135例成人(>18岁)未控制CRSwNP患者。
- 度普利尤单抗300 mg每两周皮下注射,随访6和12个月。
- 基线数据包括人口学、病史、既往手术、相关共病、内镜下鼻息肉总分(NPS)、SNOT22、鼻塞视觉模拟量表(VAS)和鼻阻塞评估量表(NOSE)、嗅觉丧失评分(LSS)及嗜酸性粒细胞计数。
主要发现
- 治疗6和12个月后所有临床参数均显著改善。
- 安全性良好,无严重副作用发生,无需补救治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Research on the immune mechanism behind chronic rhinosinusitis (CRS) has revealed various new endotypes, leading to targeted therapies, especially for severe uncontrolled CRS. Biologics are novel therapeutic strategies providing targeted treatment for the difficult-to-treat recalcitrant CRSwNP patients. Dupilumab is a fully human-derived monoclonal antibody that binds to IL4Rα, inhibiting the signalling of both IL-4 and IL-13. In Hungary, it is approved for the treatment of uncontrolled CRSwNP according to criteria based on the EPOS2020 and the Hungarian guidelines. METHODOLOGY: This study aimed to collect and evaluate real-world therapeutic data of CRSwNP patients treated with dupilumab. One hundred thirty-five patients from eight different referral centres have been enrolled in this study, who received dupilumab since 2020. All subjects were adult patients (over 18 years) with uncontrolled CRSwNP. Baseline data collection included demographics, medical history, previous surgeries, related comorbidities, total endoscopic nasal polyp score (NPS), SNOT22, nasal congestion parameters measured with visual analogue scale (VAS) and nasal obstruction evaluation scale (NOSE), loss of smell score (LSS) and eosinophil count. 300 mg dupilumab was administered subcutaneously every second week. Follow up visits were performed after 6 and 12 months. RESULTS: After 6 and 12 months of treatment significant improvement was detected in all clinical parameters. Safety was proved, no severe side effects occurred, and no rescue treatment was necessary. CONCLUSIONS: Our real-life findings show that continuous dupilumab treatment is effective and safe in daily clinical practice in CRSwNP and other type 2 comorbidities such as bronchial asthma and NERD.
引用
- Kiricsi A, Bella Z, Kraxner H, et al. Real-life effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps. Results from eight Hungarian centres with 12-month follow-up. Rhinology. 2024. PMID: 38848046. doi:10.4193/Rhin23.278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。